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Abstract:9
Asthma is a complex respiratory disease, with both genetic and environmental10
factors contributing to disease susceptibility. Genome-wide Association Studies11
(GWAS) have now identified novel risk alleles and loci associated with asthma12
diagnosis and more recently clinical sub-groups of disease. However, while providing13
insight into potential disease mechanisms these risk alleles have modest effect sizes14
and account for a small proportion of the anticipated heritability of asthma. In this15
review we provide an overview of GWAS in asthma to date including reproducible16
associations and advances in our understanding of the biology of asthma. In addition17
we discuss ancestry specific findings and how genetics may contribute to the18
development of multiple allergic conditions known as the ‘atopic march’. Finally, we19
outline the strengths and weaknesses of GWAS and look to future approaches20
including a greater focus to functional variation and assessment of gene-gene and21
gene-environment interactions.22
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2Key Concepts:1
 Asthma is a common respiratory disease that is heterogeneous with respect2
to its underlying pathology and clinical presentation.3
 Susceptibility to develop asthma involves both genetic and environmental risk4
factors.5
 Genome wide association is the current method of choice to identify genetic6
factors underlying complex, multifactorial diseases such as asthma with7
sufficient confidence.8
 GWAS of asthma have identified several genetic risk factors and genes with9
confidence, e.g. IL33, IL1RL1, ORMDL3 loci. Replication of findings remains10
the gold standard.11
 GWAS of sub-groups of asthma e.g. childhood onset disease have identified12
specific genetic risk factors.13
 The effect sizes identified in GWAS are typically modest for single variants.14
 GWAS have provided a unique insight into the altered biology of asthma15
including changes in innate and adaptive immune responses, altered airway16
smooth muscle function and epithelial barrier/function abnormalities.17
 While GWAS of asthma have been successful there remains a large missing18
heritability.19
 Future approaches include better clinical definition of asthma and greater20
interrogation of genetic factors not currently addressed e.g. regulatory21
variants, rare variants, copy number variants and greater attention to gene-22
environment interactions, gene-gene interactions and epigenetic mechanisms.23
24
3Introduction:1
Asthma is a common respiratory disease characterised by acute episodes of2
breathlessness, chronic inflammation of the airways, reversible airflow obstruction3
and increased airway hyper-responsiveness to a variety of environmental stimuli and4
allergens (1). Asthma is a complex disease with a large degree of heterogeneity in5
the age of onset, the nature of triggers, the severity of symptoms and the6
contribution of atopy. There is now compelling evidence that asthma is effected by7
the joint action of both genetic and environmental risk factors in addition to their main8
effects (2). It affects both children and adults and commonly exists with comorbidities9
including other allergic diseases such as Allergic Rhinitis (AR) and Atopic Dermatitis10
(AD), which also have substantial heritability (3). Genome-wide association studies11
(GWAS), which involve the testing of typically 500,000+ genetic variants for12
association with the disease, are currently the preferred method for studying13
complex multifactorial diseases such as asthma.14
In this review, we discuss recent advances in our understanding of the genetic basis15
of asthma that have come from GWAS, including the strengths and limitations of16
these genetic approaches. Additionally, we discuss the new insights into the biology17
of asthma provided to date. Finally, we outline future directions in this area including18
improved phenotype definition and additional genetic approaches to identify19
causative variants.20
Asthma is a complex genetic disorder21
It has been known for over 100 years that asthma and atopic diseases asthma run in22
families. Using 621 atopic probands and 76 non-atopic controls and their families, it23
was shown in 1916 that 48.4% of atopic probands had a family history of atopy,24
compared with just 14.5% in the control population (4). Similarly, a very high25
concordance of asthma, AR and AD in parents and children was established in the26
1970s in a study of 176 families (5). Twin studies have been instrumental in27
identifying a significant concordance of asthma that is higher in monozygotic twins28
(identical genotype) than in dizygotic twins (on average sharing half of their genes).29
A recent study using 25,306 twins aged 9 or 12 years identified the heritability of30
childhood asthma to be 82%(6). Overall genetic factors are thought to account for31
60-80% of the susceptibility to develop asthma with a smaller effect attributable to32
environmental factors, however this does not preclude that the environment is33
important.34
4Therefore, asthma is considered a complex genetic disorder and, in contrast to1
single-gene disorders (e.g. cystic fibrosis), involves multiple genes with expression2
influenced by both genetic and environmental factors. Several environmental factors3
are important in asthma development including tobacco smoke exposure, respiratory4
viral infections, antibiotic use, diet, and allergen exposure. In particular, early-life5
exposures play an important role. Gender and ethnic background also have a6
significant contribution. Environmental contributions to asthma risk is nicely7
demonstrated by two key observations; i) the increase in asthma prevalence in8
developed countries over the last few decades and ii) the differences in asthma9
prevalence between rural/farming and city/non-farming children which cannot be10
driven by genetic factors alone (7). This complex mode of inheritance, combined with11
the heterogeneity in the presentation of the disease and differing environmental12
influences has made gene discovery in asthma a challenge. See also DOI:13
10.1002/9780470015902.a0005565.pub214
15
Methods for gene identification: The move to Genome Wide Association16
Studies (GWAS) for complex disorders17
Early studies of the genetics of asthma investigated inheritance through families18
containing multiple affected children, using linkage analyses and candidate gene19
approaches based on biology or location in the genome. However, the reproducibility20
of these findings was limited primarily because of inadequate power, subject21
heterogeneity (different phenotype definition), population stratification, and multiple22
testing without correction. This aside, several genes/loci where identified with23
confidence including; DPP10, PCDH1, HLAG, NPSR1, PHF11, PLAUR, ADAM33,24
IL10, CD14, IL4, IL13, ADRB2, HLA-DRB1, HLA-DQB1, TNFA, FCER1B, INPP4A,25
STAT6 and IL4RA providing a novel insight into asthma biology (For excellent26
reviews see (8, 9)).27
Our understanding of the complexity of genetic variation present in the human28
genome has improved dramatically with sequencing initiatives such as the HapMap29
project, 1000 genomes and most recently the 100,000 genomes projects. Recent30
figures suggest > 60 million single nucleotide polymorphisms (SNP) or single base31
pair changes exist in humans. Similarly, there is a growing realization that deletions,32
insertions, and expansions of tandem repeats also represent significant variation.33
Technological advances enabling the simultaneous genotyping of >1 million SNPs34
allows for the investigation of the role of polymorphisms spanning the entire genome35
in cases and controls with very stringent statistical thresholds, e.g. P<5 x 10-8 to36
account for the large number of tests completed. See Figure 1 for an overview of37
5approaches used to identify genetic loci associated with asthma diagnosis. See also1
DOI: 10.1002/9780470015902.a0021458 and DOI: 10.1002/9780470015902.a00219952
Insert Figure 1 here3
In the following sections we provide an overview of current findings of recent GWAS4
for i) self-reported/doctor diagnosed asthma and ii) asthma that has been refined5
clinically to a specific sub-population of asthma patients, namely; childhood onset6
asthma, severe asthma, asthma with frequent exacerbation, asthma with co-7
morbidities, including allergic rhinitis, atopy, COPD and gender specific analyses.8
Genetic associations identified in GWAS of asthma diagnosis9
The first asthma GWAS was completed in 2007 and utilised a discovery cohort of10
994 patients who presented with childhood onset asthma in comparison to 1,24311
non-asthma controls (10). This GWAS identified a significant association to a locus12
on chromosome 17q21 that included multiple genes of interest, including genes for13
a) zona pellucida binding protein 2 (ZPBP2), b) gasdermin B (GSDMB) and c) orm114
like protein 3 (ORMDL3). Over time, this 17q21 locus has been confirmed as an15
association locus in independent studies with asthma (11), severe asthma (12) and16
asthma with severe exacerbations (13) as phenotypic end-points. Further evidence17
of the importance of this first GWAS defined locus has come through associations18
with several asthma-relevant clinical measures in independent cohorts such as lung19
function, bronchial hyper-responsiveness (BHR) and disease severity for the key20
17q21 GWAS SNPs (14). However, the specific underlying gene(s) that explain the21
genetic association remains to be resolved and it is likely that multiple genes are22
underlying the signal(s). ZPBP2, GSDMB and ORMDL3 have been reported to have23
a role in gene transcription, cell apoptosis and sphingolipid synthesis respectively.24
Recently a role for ORMDL3 in eosinophil trafficking and degranulation, mechanisms25
thought to be important in asthma, has been identified (15).26
There are now more than 50 studies registered with the NHGRI-EBI catalog of27
published GWAS for asthma and related traits (16). Typically, these studies include28
between 300-2,000 asthma subjects and therefore may be anticipated to identify29
~50% of associations for common variants (minor allele frequency 10-50%) (17). A30
summary of the main findings from these asthma GWAS is shown in Table 1,31
focussed to loci that have been identified in the Caucasian population and have been32
verified by replication.33
6It was realised early on that very large numbers of subjects would be needed to1
identify genetic variants associated with asthma diagnosis with sufficient confidence2
to overcome the issues of differential asthma definition, ancestry diversity and the3
large number of known environmental factors contributing to susceptibility. The4
largest of these meta-analyses to date is the study carried out by the European5
GABRIEL (A Multidisciplinary Study to Identify the Genetic and Environmental6
Causes of Asthma in the European Community) consortium involving 10,365 cases7
and 16,110 controls (11). This study used primarily doctor diagnosed asthma as an8
end point identifying association to loci spanning multiple genes, including: IL33,9
IL1RL1/IL18R1, HLA-DQ, SMAD3, IL2RB and the 17q21 locus (11). Similarly, there10
has been a US led meta-analyses, the EVE consortium, consisting of 3,246 asthma11
cases and 3,385 controls and additional cohorts (1,702 case-parent trios, 355 family12
based cases and 468 family based control) including subjects from European, Latino13
and African ancestry (18). Four previously described loci associated in Caucasian14
subjects were identified; 17q21, IL1RL1, IL33 and TSLP (18). Therefore, to date 1215
asthma susceptibility loci have been identified using asthma diagnosis as and end16
point (Table 1) however it is important to note that the effect sizes of any single17
variant is modest, odds ratio (OR) 1.1-1.4. Overall the susceptibility genes identified18
to date are consistent with the hypothesis that asthma is caused by epithelial19
barrier/function abnormalities and altered innate and adaptive immune responses. It20
was reported by the GABRIEL consortium that ~49% of the lifetime risk of asthma21
could be explained by the loci identified in this study (11).22
Insert Table 1 here.23
Clinical refinement of asthma for GWAS24
There is accumulating evidence that asthma is a heterogeneous condition involving25
multiple sub-groups with potentially different underlying causation, clinical26
presentation and therefore genetic basis. These groups have been identified through27
approaches such as cluster analyses that examine clinical (e.g. lung function),28
immunological (e.g. blood inflammatory cells) and epidemiological data (gender, age29
of onset) (19-21). A recent study combined this clustering of phenotypic information30
in 3,001 asthma subjects to identify four asthma groups and then completed a31
GWAS which identified novel genetic associations for i) active adult-onset non-32
allergic asthma and CD200 and ii) inactive/mild non-allergic asthma with GRIK2 (22).33
7Of these sub-groups, asthma age of onset has emerged as an important phenotype1
for asthma development. From a genetic perspective, heritability estimates have2
been shown to be inversely correlated with age of onset , suggesting that in3
childhood onset disease genetic factors are more important (23). This same study4
also demonstrated that genetic factors explained 34% of the variation in the age at5
onset of and environmental factors 66% (23). Also, as a sub-analyses of the6
GABRIEL study, chromosome 17q21 was identified as a specific locus for childhood7
onset asthma (11), similarly GWAS of mild-moderate childhood asthma with8
methacholine sensitivity and moderate-severe childhood asthma identified PDE4D9
and DENND1B loci respectively ((24, 25) Table 1).10
Multiple recent studies have now started to investigate different sub-phenotypes of11
asthma to try and identify genetic drivers of specific asthma phenotypes. Such12
phenotypes have included: i) increased asthma exacerbations in patients taking13
inhaled corticosteroids (26), ii) early childhood asthma with exacerbations (13), iii) in14
never/low smoking asthma subjects (27) and moderate-severe asthma (12). These15
studies have identified several variants distinct to those previously reported for16
asthma diagnosis such as CDHR3 for early childhood asthma with exacerbations17
(13). Interestingly, for several previously identified regions of interest, the median18
effect size reported was higher in studies with a refined clinical phenotype,19
suggesting that interpretation of doctor diagnosed asthma GWAS requires caution.20
However, this is not all together surprising as some loci will be of greater importance21
for different subsets of asthma patients. This is exemplified in the GWAS for severe22
asthma with exacerbations were the number of hospitalisations reported positively23
correlated to the SNP effect sizes, including those in the IL33 locus (e.g. OR 1.32,24
1.22, 1.47, 1.91 for 2, 3, 4/5 and 6 or more hospitalisations respectively) (13).25
Focussing to moderate-severe asthma, a recent UK study did not identify any novel26
locus meeting genome wide significance in the discovery analyses with suggestive27
data for novel loci e.g. C5orf56, CD83 however this study confirmed previous signals28
at 17q21 and the IL1RL1 loci in the combined analysis (12). As illustration we have29
included the Manhattan plot and 17q21 region plot from this study of moderate-30
severe asthma to demonstrate typical findings from a GWAS (Figure 2). In a similar31
approach focussed to severe, difficult to treat asthma subjects as part of the The32
Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens33
8(TENOR) study did not identify novel loci however association to the IL13/RAD501
locus was confirmed (28).2
Insert Figure 2 here.3
4
Stratification has also included investigations into co-morbidities commonly5
associated with asthma such as asthma-COPD (29) and asthma-AR (30) overlap.6
The presence or absence of these co-morbidities with asthma may be triggered by a7
distinct and overlapping genetic profile. Loci associated with the combined8
phenotype were attenuated or absent when each phenotype was investigated in9
isolation when compared to the combined phenotype, again highlighting the need to10
consider asthma as a more complex and multi-stratified disease. Potential genetic11
associations included SNPs in genes: CSMD1, SOX5, for asthma/COPD (29) and12
ZBTB10, IL33, IL1RL1, SMAD3, TSLP, c11orf30, ORMDL3 and CLEC16A for13
asthma/AR (30) (see Table 1).14
Interestingly, stratification of asthma patients based on gender has recently15
led to the discovery of novel genetic determinants (31), suggesting that gender-16
stratification of asthma GWA has an important role to play in dissecting the genetic17
architecture of asthma. Another study confirmed the importance of gender-linked18
association by comparing three groups consisting of 2566 female cases, 2653 male19
cases and 3830 controls identifying four female specific association loci20
(Rap1GAP2/17p13.3, C6orf118/6q27, ERBB4/2q34, AK057517/2q23.3) and two21
male loci (IRF1/5q31.1, RAB11FTP2/10q26.11) in multiple ancestry groups (32).22
Therefore while data generated by GWAS of asthma focussed to specific sub-23
groups of patients is only just emerging, it is clear that these analyses have identified24
overlapping and distinct genetic loci from asthma diagnosis adding further to the25
concept that genetics may contribute to the differential expression of asthma (see26
Figure 3).27
Insert Figure 3 here.28
Results of GWAS in other ethnic populations29
Although the majority of GWAS to date have focussed to populations of European30
descent, recent studies have also considered other ancestries including African31
American, Mexican, Korean and Japanese cohorts. Torgerson et al. have used32
diverse North American populations including 5,416 individuals with asthma of33
9European American, African American or African Caribbean, and Latino ancestry1
with replication in 12,649 individuals from the same ethnic groups (18). Four2
previously described loci associated in Caucasian studies were identified; 17q21,3
IL1RL1, IL33 and TSLP. However, importantly there appears to be some ancestry4
specific loci e.g. the 17q21 loci was particularly relevant to the Caucasian and Latino5
populations and a novel locus, PYHIN1 was identified in populations of African6
ancestry only (18). PYHIN1 encodes pyrin and HIN-domain family, member 1 and is7
an interferon inducible protein shown to regulate IFN- and NO production in8
macrophages. Ancestry specific associations have also been identified in other9
populations. In the largest GWAS of asthma in the Japanese population to date,10
7,171 cases and 27,912 controls were used to identify five loci; 4q31 (USP38-11
GAB1), 5q22 (TSLP), 6p21 (HLA), 10p14 (intergenic) and 12q13 (IKZF4) (33).12
13
Overlap with other allergic diseases – the atopic march?14
There is accumulating evidence that allergic diseases e.g. asthma, AR, AD and traits15
e.g. serum IgE, blood eosinophil counts share a large number of genetic16
susceptibility loci (3). Of note genetic polymorphisms within the IL33 and IL1RL117
(IL33 receptor) loci are thought to be of relevance for asthma, AD, allergic18
sensitisation and blood eosinophil counts suggesting the IL33 pathway may19
represent an underlying mechanism and therapeutic opportunity. Polymorphisms20
spanning C11orf30/LRRC32 also show association with these traits. These21
overlapping loci may at least in part explain the concept of the “atopic march” e.g.22
childhood AD leads to an increased risk of developing asthma, as there is23
overlapping genetic susceptibility to both conditions. It is important to note that there24
is also clear trait specificity for many loci, most evident for e.g. the FLG locus for AD.25
Due to the common occurrence of comorbidities it is difficult to define which26
susceptibility loci are shared or specific. As discussed earlier, there is move to a27
more comprehensive phenotype definition in asthma genetics including stratification28
based on co-morbidities. One recent study aimed to address this for asthma and AD29
by stratifying patients based on AD (all), AD and asthma, and AD (no asthma) (34).30
Using a cohort of 1,563 childhood onset AD cases and 4,054 controls, five loci were31
identified as genome wide significant in all subjects; of interest the 1p21 (FLG) and32
5q31 (RAD50/IL13) loci achieved markedly greater significance in the AD plus33
10
asthma compared to the AD (no asthma) group (34). More recently, a GWAS in1
infantile AD followed by childhood asthma using 2,428 cases and 17,034 controls2
identified both novel loci (EFHC1 on 6p12.3 and TMTC2/SLC6A15 on12q21.3) and3
loci previously associated with multiple allergic traits (FLG (1q21.3), IL4/KIF3A4
(5q31.1), AP5B1/OVOL1 (11q13.1), C11orf30/LRRC32 (11q13.5) and IKZF35
(17q21)) (35). This study provides further evidence for a genetic contribution to the6
atopic march. See also DOI: 10.1002/9780470015902.a0001887.pub37
8
What have we learnt so far – biology9
Genetic findings from asthma GWAS have provided novel insights into the potential10
molecular mechanisms that underlie asthma development. For example HLA is11
anticipated to be important for T-cell-mediated inflammatory responses as is IL2RB,12
which is an intermediate molecule for T-cell survival. The signalling molecule,13
SMAD3, is known to be involved in fibrosis. Asthma GWAS results identifying loci14
related to interleukin 33 (IL33) and interleukin 33 receptor (IL1RL1 or ST2) genes15
have identified mechanisms of relevance related to allergic sensitisation and blood16
eosinophilia (through other GWAS). These associations to IL33 and IL1RL1 were17
replicated in subsequent GWAS for asthma and severe asthma phenotypes (12, 13,18
36) confirming their role. IL33 has been shown to be elevated in the airways of19
asthma patients; particularly in the airway structural cells including the bronchial20
epithelium, while the soluble form of its receptor ST2 encoded by IL1RL1 was shown21
to be elevated during asthma exacerbation. Functional genetics, following GWAS22
results have allowed for the determination of putative mechanisms for GWAS23
identified polymorphisms, specifically those known to alter amino acid residues. An24
example of such is the functional genetic study focussing to the IL1RL1 locus which25
has shown that the GWAS tagged SNPs may influence IL33 and sST2 production26
(37).27
28
Overall to date genes identified may be involved in diverse roles such as the function29
and activation of inflammatory cells (IL13, IL6R, DENND1B, LRRC32, IL2RB, and30
IL1RL1), airway smooth muscle contraction (PDE4D), and cell apoptosis and31
11
differentiation (GSDMB). This once more provides insight into the potential1
mechanisms of action that are involved in the development and modulation of2
asthma. Of special note is that a significant number of genes (e.g. IL33, IL1RL1,3
C11orf30 and TSLP) that are known to be associated with epithelial cell functions4
and homeostasis. This further supports the hypothesis that the bronchial epithelium5
is altered in asthma (38). Further evidence for this concept is the recent finding that6
polymorphisms spanning CDHR3 are associated with severe asthma with7
exacerbation (13). CDHR3 encodes cadherin-related family member 3, with other8
family members being involved in epithelial polarity and cell-cell interactions. Recent9
data suggest that CDHR3 is the receptor for Rhinovirus, the most common10
respiratory virus associated with exacerbations in asthma, and that the key variant11
identified in GWAS modulates levels of CDHR3 providing a putative mechanism12
(39).13
Of note is that, for the majority of asthma susceptibility loci identified to date it14
is unclear what are the key causative variants and genes(s) underlying the15
association. There are intensive efforts to close this gap in knowledge using16
approaches such as linkage disequilibrium mapping and eQTL analyses in lung17
tissue and lung relevant cells.18
19
GWAS strengths and weaknesses: Reproducibility between approaches and20
missing heritability21
While GWAS have many design/technological strengths including the ability to22
interrogate the genome on an unprecedented scale, the hypothesis free nature of the23
approach and the potential to identify causative variants it is important to note that24
GWAS to date in asthma have only been able to identify common variants with25
modest effect sizes (OR: 1.1-1.4) and have shown limited concordance with previous26
work. The lack of concordance between approaches (e.g., linkage versus GWAS)27
can be explained by the fact that the methodologies are designed to detect different28
types of variants (e.g., linkage analysis has good power to detect high-risk disease-29
causing alleles but is not effective at identifying common alleles of modest effect size30
as GWAS does). It is reassuring that many of the genes identified in candidate gene31
approaches have been reproduced in GWAS (e.g., the IL13/IL4 locus on32
chromosome 5q31). Another key limitation of current GWAS in asthma is that SNPs33
12
chosen for array design were not selected specifically for function. This means that1
results reported to date using very stringent statistical approaches represent “the low2
hanging fruit” and it is likely that causative SNPs exist in the statistical significance3
range <10-4 or have simply not been interrogated yet (40). These considerations4
underlie the observation that variants identified by GWAS in asthma account for only5
a small fraction of the heritability, a concept that is called the “missing heritability”6
(41). Additional possible explanations to account for missing heritability include, i)7
rare variants with larger effect size not measured on existing platforms, ii) structural8
variation e.g. copy number variation, iii) gene-environment contributions, iv) gene-9
gene interactions v) epigenetic mechanisms and vi) overestimation of initial10
heritability.11
12
Future Directions13
It is beyond doubt GWAS in asthma have significantly increased our understanding14
of the genetic architecture of this complex respiratory disease and provided a novel15
understanding of potentially altered biology in the disease. These genetic findings16
highlight alterations in innate and adaptive immune responses, airway smooth17
muscle function and epithelial barrier/function. The future holds great promise to18
extend these studies particularly beyond asthma diagnosis to further define asthma19
sub-phenotypes with recent success including childhood onset asthma (17q21),20
childhood severe asthma with exacerbation (CDHR3) and identifying novel genetic21
determinants underlying the atopic march from AD to asthma (EFHC1 and22
TMTC2/SLC6A15). Therefore, in addition to larger International Consortia involving23
tens of thousands of subjects investigating asthma diagnosis with improved power24
we also anticipate a drive to GWAS in refined studies of carefully characterised25
patients. This shift in focus is at least in part driven by the greater appreciation that26
asthma is heterogeneous and while very large numbers have been able to identify27
the “low hanging fruit” future approaches need to be focussed to asthma patients28
with more thorough clinical characterisation.29
Data from GWAS of several human traits/diseases including asthma suggest that the30
majority of associated common SNPs are found in regulatory regions not in the31
13
coding regions of genes and that these regions are enriched for e.g. DNase I1
hypersensitivity sites. Therefore the design of current platforms for GWAS is also an2
area of intense focus with greater emphasis on validated functional variation3
identified in initiatives such as Encyclopaedia of DNA Elements Consortium4
(ENCODE) (42) being a priority. Significant advances in our understanding of5
expression trait quantitative loci (eQTL) importantly in airway relevant cells and in6
lung tissue (43, 44) have helped identify potentially functional SNPs driving mRNA7
levels in both a cis and trans mechanism. These initiatives and improved sequencing8
information on rare variants were fundamental in the design of arrays used in UK9
initiatives such as the custom Affymetrix® array for UK Biobank, a study of 502,68210
participants in the UK.11
In addition to GWAS additional approaches are being used including exome12
sequencing and candidate gene resequencing which suggested an increased13
heterogeneity in asthma and the importance of rare variants. As costs for targeted14
resequencing and whole genome sequencing continue to decrease this makes15
approaches to investigate variation per se on a large scale a real possibility. The16
integration of environmental factors, known to be an important contributing factor in17
asthma will be a focus for research efforts allowing gene-environmental interaction to18
be identified beyond those identified for single genes e.g. interaction between CD1419
rs2569190 and endotoxin exposure determining disease risk (2). The environment is20
particularly important for epigenetic changes driving disease, with accumulating21
evidence that the epigenome may be important in allergic diseases such as asthma.22
Recently, a genome-wide methylation association study identified a significant23
contribution of CpG islands in determining serum IgE levels, a major driver of24
multiple allergic diseases including allergic asthma (45).25
In summary, future approaches to asthma gene discovery and translation will26
include: improved clinical definition, integrated models that include interactions with27
environmental factors, GWAS data from custom/functional arrays, epigenetic data,28
eQTL analyses, emerging sequencing approaches leading to pathways analyses29
and biological approaches. Overall a greater understanding of genetic variation in30
specific pathways which results in increased risk of developing asthma will generate31
greater understanding of the biology of this complex disease. This represents the32
14
first stage to clinical translation and the development of new more effective1
treatments for asthma.2
3
4
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Figures and Table1
Reported Gene(s) Locus Biology Associatedend-point Study (reference)
IL6R 1q21 Regulatory T-cell function, T-celldifferentiation A (46)
DENND1B 1q31 Memory T-cell function B (25)
IL1RL1/IL18R1, SLC9A4 2q12 IL-33 receptor/sodium-hydrogenexchanger A, B, C, D (11, 12, 18, 30)
CD200 3q13 T-cell proliferation E (22)
TLR4 4p14 Pathogen recognition and activationof innate immunity D (30)
PDE4D 5q12 Cell signalling, inflammation, ASMfunction B (24)
TSLP 5q22 Activates dendritic cells, Th2immune responses A, D (18, 30)
SLC22A4/RAD50/IL13/KIF3A 5q31 Organic cationic transporter/DNArepair/Th2 cytokine/cilia protein A, C, F (11, 13, 28)
IRF1 5q31 Involved in B lymphocyteexpression G (32)
HLA-DRA/DRQ 6p21 T-cell responses/many additionalgenes in region A, C (11, 28, 36, 47)
GRIK2 6q16 Excitatory neurotransmitter H (22)
CDHR3 7q22 Epithelial polarity, cell–cell contactand differentiation F (13)
CSMD1 8p23
Regulator of complement activation
and inflammation in the developing
central nervous system
I (29)
ZBTB10 8q21 May be involved in transcriptionalregulation D (30)
IL33 9p24 Recruitment/activation ofinflammatory cells A, D, F (11, 13, 30, 48)
C11orf30/LRRC32 11q13
Regulates gene expression,
epithelial barrier/regulatory T-cell
function.
A, D (30, 46)
SOX5 12p12 Controls expression of extracellularmatrix genes and cell proliferation I (29)
SMAD3 15q22 TGF-β signalling intermediate,fibrosis A, D (11, 30)
CLEC16A 16p13 Inflammatory cell function (ITAMreceptor), Regulator of mitophagy D (30)
ORMDL3/GSDMB/ZPB2 17q21 Sphingolipid synthesis/cellapoptosis A, B, C, D (10-12, 30)
IL2RB 22q12 Binds IL-2/IL-15, lymphoid celldifferentiation A (11)
2
Table 1: Susceptibility genes for asthma diagnosis or asthma stratified into specific sub-3
groups identified by Genome Wide Association Studies (GWAS). A: Asthma Diagnosis, B:4
Childhood asthma, C: Severe Asthma, D: Asthma with a diagnosis of AR, E: Active adult-5
onset non-allergic asthma, F: Childhood severe asthma with exacerbation, G: Asthma6
associated with the male gender, H: inactive/mild non-allergic asthma, I: Asthma with a7
diagnosis of COPD. Data is focused to studies using individuals with Caucasian ancestry.8
9
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Figure 1: Asthma Gene Discovery Methods. Positional cloning involves linkage analyses6
which follows the transmission of genetic information through families with multiple7
affected children followed by fine association mapping. Genome Wide Association Studies8
(GWAS) looks at the frequency of a large number of common variants between cases and9
controls. Both approaches lead to novel gene discovery. Reproduced with permission from10
(1).11
12
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Figure 2: Manhattan (A) and chromosome 17q21 region (B) plots from the GWAS of3
moderate-severe asthma. Multiple suggestive signals (P<10-5) are apparent (red) and closer4
examination of 17q21 (B) illustrates the complexity of the signal demonstrating how5
A
B
19
identification of the causative variant and gene can be a challenge. Reproduced with1
permission from (12).2
3
4
Figure 3: Schematic illustrating genetic loci identified in GWAS for asthma diagnosis or5
asthma stratified into specific sub-groups. Multiple signals identified in different6
populations are highlighted in the main blue box. Signals specific to the male gender are7
highlighted in yellow, while genes associated to asthma with co-morbidities are highlighted8
in their respective boxes. Loci associated with a specific sub-set of asthma are listed in their9
respective groups a top the main box. Genes that are relevant to different groups presented10
in box overlaps. Where overlap was not possible, genes presented multiple times in the11
diagram are highlighted with an asterisk.12
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20
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